Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2013 Earnings Results

Catalyst Pharmaceuticals Misses on EPS, Stock Up 1.4%

Catalyst Pharmaceuticals reported a loss per share that was worse than expected, which typically raises concerns among investors. However, the stock reacted positively, increasing by 1.4%. This could indicate that investors are optimistic about the company's future plans despite the EPS miss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.08	N/A	-14.29%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about the company's direction. They are focused on improving their product portfolio despite recent challenges.

Management highlighted ongoing efforts to enhance product offerings.

They acknowledged the challenges faced but expressed commitment to future growth.

Catalyst Pharmaceuticals Misses on EPS, Stock Up 1.4%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Misses on EPS, Stock Up 1.4%

Key numbers

Management commentary